News | August 01, 2025
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
NewCo’s pipeline includes five investigational medicines
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
Subscribe To Our Newsletter & Stay Updated
